David Charles Blakey

USPTO Granted Patents = 10 (Patent Applications = 8)

EPO Patents = 2 (Patent Applications = 5)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 115(Granted Patents)

Company Filing History:

Years Active: 1997-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10066011 - Antibodies directed to angiopoietin-2 and uses thereof (2018-09-04),

2. 8834880 - Antibodies directed to angiopoietin-2 and uses thereof (2014-09-16),

3. 8697664 - Targeted binding agents directed to PDGRF-alpha and uses thereof (2014-04-15),

4. 7973140 - Antibodies directed to angiopoietin-2 and uses thereof (2011-07-05),

5. 7754859 - Targeted binding agents directed to PDGFR-alpha and uses thereof (2010-07-13),

6. 7030123 - Indole derivatives with vascular damaging activity (2006-04-18),

7. 6436691 - Chemical compounds (2002-08-20),

8. 6339070 - Gene construct encoding a heterologous prodrug-activating enzyme and a cell targeting moiety (2002-01-15),

9. 5985281 - Chemical compounds (1999-11-16),

10. 5665357 - Antibodies recognizing tumor associated antigen CA 55.1 (1997-09-09),

Title: David Charles Blakey: Innovator in Antibody Technology

Introduction

David Charles Blakey is a distinguished inventor based in Macclesfield, GB, known for his significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a portfolio of 10 patents, Blakey has made remarkable strides in innovation, focusing on therapeutic applications that address critical health issues.

Latest Patents

Among his most notable patents are those related to antibodies directed to angiopoietin-2 (Ang-2). These inventions detail fully human monoclonal antibodies that target the Ang-2 antigen, offering new possibilities in treatment approaches for diseases associated with angiogenesis. Specifically, his patents include nucleotide sequences encoding heavy and light chain immunoglobulin molecules, as well as hybridomas or other cell lines expressing these immunoglobulin molecules. The detailed specifications cover sequences that span the framework regions and complementarity determining regions (CDRs) important for the efficacy of these antibodies.

Career Highlights

David Blakey has had a fruitful career, marked by his tenure at prominent companies such as Zeneca Limited and MedImmune Limited. During his time at these organizations, he contributed to various research projects that advanced the field of immunotherapy. His innovative work is recognized in the medical community, reflecting his commitment to improving health outcomes through scientific discovery.

Collaborations

Throughout his career, Blakey has collaborated with notable professionals in the field, including Stephen Charles Emery and Larry L Green. These collaborations have fostered a rich exchange of ideas and expertise, further enhancing the development of effective biotechnological solutions.

Conclusion

David Charles Blakey's innovations in antibody technology and his extensive patent portfolio underscore his significant impact on the field of biotechnology. His work not only advances scientific knowledge but also holds promise for transformative therapies in the medical landscape.

This text is generated by artificial intelligence and may not be accurate.